Archive | January, 2011

Bullish Action in Biotech Today

The melt-up resumes. Everyone talks about the really big correction but all we get is a measly 2-3% hit then onward and upward. Metals and materials were ~2% winners today and the NAZ was up 0.75%. Titanium (TIE) was up 7.9 % . What’s with that? Although healthcare was up only 0.4% there was plenty […]

Continue Reading 0

Rayno Snow Blog: LaNina Mid-Winter Drought

High and Dry in the West Why am I reporting on snow? There is none and little hope for the next seven days-maybe longer. If you like cool sunny dry weather come to  SoCal.If you like snow go to NYC or Vancouver BC.I am booking MT for mid-February. Mammoth Lakes Weather brought to you by […]

Continue Reading 0

Amgen(AMGN) To Buy Biovex For Cancer Vaccine Technology

Biologics for Treatment of Cancer and Prevention of Infectious Disease Amgen(AMGN) and  Biovex said today that both Boards approved the sale of privately held Biovex for $425M with milestone payments as much as $525M. The Biovex lead product OncoVex, an oncolytic vaccine, is in a Phase III multinational study for metastatic melanoma. A second study […]

Continue Reading 0

Life Science News Update:$700M in Fed Research Center at NIH; AD Diagnosis

Will the GOP cut the NIH budget? Turf battles at the Institutes to follow. Who knew there were only two breakthroughs in mental health drugs: Thorazine and Lithium? Federal Research Center Will Help Develop Medicines – NYTimes.com Most experts believe the PET Imaging procedure can be helpful. Alzheimer’s Scan Might Help Spot Disease Alzheimer’s Association […]

Continue Reading 0

Biotech Movers du jour: Clinical Data (CLDA) and Genoptix (GXDX)

Novartis (NVS) acquires Genoptix(GXDX $24.84) for $470M-Stock is up 25% The biotech diagnostics and tools sector was ignited today with acquisition of Genoptix, a provider of laboratory services for hematology and oncology. Genoptix put itself up for sale in December and is an emerging niche player in personalized medicine with revenues of about $200M and […]

Continue Reading 0

Venture Capital Recovers, Biotechnology Gets $3.7B in 2010

Venture Capitalists invested $21.8B in 2010 an increase of 19% over the prior year. Biotechnology was up 3% over the prior year to $3.7B with 460 deals. Software was the leader rising 20% to $4B. Medical Device was flat year over year with $2.3B invested. ANNUAL VENTURE INVESTMENT INCREASES FOR FIRST TIME SINCE 2007, ACCORDING […]

Continue Reading 0

Rayno Life Science Portfolio 2011:Time to Raise a Little Cash

Time for Caution-Raise Cash After the Big Q4 2010 Run Here are some guidelines for the Rayno Life Science Portfolio: Smaller cap high beta biopharma stocks are at risk. No new buys. Our mid-cap index is still weak. Tools and diagnostics will be less volatile. ABAX, GPRO, ILMN. Raise cash or hedge by pruning winners […]

Continue Reading 0

Biotech Stocks Sell-Off On Profit Taking: Traders Rule

Small to Mid Caps Off 3%+ Our Mid-Cap Index of biotech stocks was off 3% and more today. Among the big movers down on significant volume were: Alkermes (ALKS)  down 4.19%, Arena (ARNA) down 4.25%, Biodel (BIOD) down 9.5%, Sangamo (SGMO) down 8.75%, Jazz (JAZZ) down 4.25% and Vivus (VVUS) down 6.35%. Mannkind (MNKD) off […]

Continue Reading 0

Reporting from the JPMorgan 29th Annual Healthcare Conference 2011

J.P.Morgan 29th Annual Healthcare Conference San Francisco, CA January 9-13 2011 Biotechnology: Bright Prospects For 2011 Rod Raynovich The J.P.Morgan Healthcare Conference was a hot ticket in a cold city with over 8500 attendees at the St.Francis Westin Hotel. Topcoats were the unlikely fashion trend due to below normal temps (30’s). Some people complained about […]

Continue Reading 0

Rayno Life Science Portfolio Review:Celera(CRA),Qiagen(QGEN),and Gilead(GILD)

Review of the Laggards Celera (CRA $6.09) has been a laggard  primarily because of disappointing results from the recent acquisition of Berkeley Heart Labs(BHL) which had reported sales $20M vs $24M in the previous quarter in 2009.Celera has a cumulative loss in the one billion range but the shareholder equity is $576M with $300M in […]

Continue Reading 0